Drugs / Yttrium 90 Ibritumomab Tiuxetan
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00438581 | Mar 2007 → ? | non-Hodgkin lymphoma | McGill University | Unknown | No outcome recorded |
| Phase 2 | NCT00070018 | Feb 2004 → Nov 2010 | lymphoma | SWOG Cancer Research Network | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Yttrium-90 ibritumomab tiuxetan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00070018 ↗ |
| Known as | Zevalin | “Yttrium 90 Ibritumomab Tiuxetan ( Zevalin )” NCT00438581 ↗ |
| Modality | Monoclonal antibody | “Monoclonal antibodies, such as rituximab and yttrium Y 90 ibritumomab tiuxetan” NCT00070018 ↗ |
| Route | Intravenous | “yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes” NCT00070018 ↗ |